<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00018031</url>
  </required_header>
  <id_info>
    <org_study_id>010194</org_study_id>
    <secondary_id>01-I-0194</secondary_id>
    <nct_id>NCT00018031</nct_id>
  </id_info>
  <brief_title>Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients</brief_title>
  <acronym>HEPCPR</acronym>
  <official_title>A Non-Randomized, Open Label, Study to Assess Hepatitis C Viral Kinetics in Predicting the Clinical Response in Patients With Hepatitis C Infection Coinfected With HIV-1 Treated With Peginterferon Alpha-2b and Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of combination therapy with
      peginterferon alfa-2b and ribavirin for treating hepatitis C virus (HCV) infection in
      HIV-infected patients. In studies of patients with hepatitis C alone, interferon alfa-2b plus
      ribavirin treatment eradicated the HCV in almost half the patients. Peginterferon alfa-2b is
      a compound that results from attaching a polyethylene glycol molecule to interferon alfa-2b.
      This compound stays in the blood longer than unmodified interferon alfa-2b, causing a higher
      blood concentration and thus maintaining activity against the hepatitis C virus.

      HIV-infected patients 21 years of age and older with chronic hepatitis C infection and a
      viral load greater than 2000 copies/mL may be eligible for this 2 1/2-year study. Candidates
      will be screened with blood and urine tests and possibly a liver biopsy, if a recent one is
      not available. The liver biopsy is done to determine the severity of liver disease. For this
      test, patients are admitted to the NIH Clinical Center for 1 to 2 days. A sedative is
      injected into an arm vein, the skin in the area over the biopsy site is numbed with a local
      anesthetic, and a needle is inserted rapidly into and out of the liver to obtain a small
      tissue sample. The patient remains in the hospital overnight for monitoring. A chest X-ray,
      electrocardiogram (EKG) and liver ultrasound are also done. Within 4 weeks of the screening
      tests, candidates who appear eligible for the study will have a physical examination, medical
      history and repeat blood tests. Women who can become pregnant will have serial pregnancy
      tests throughout the study.

      Patients who meet the study criteria and decide to participate will begin treatment with
      weekly injections under the skin of peginterferon alfa-2b and take ribavirin pills twice a
      day by mouth. In addition, patients will continue to take all other medications prescribed by
      their doctor. Clinic visits will be scheduled as follows:

        -  Days 1, 3, 5, 7, 10 and 21 - Blood will be drawn for safety tests and to measure blood
           levels of HIV and HCV.

        -  Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 52, 56 and 64 - Blood and urine tests
           will be done to determine the side effects of treatment and its effect on the HCV
           infection.

        -  Week 48 or end of treatment - Treatment will stop after 48 weeks. At this time, or
           earlier for those who do not complete the 48 weeks, patients will return to the clinic
           for a routine test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C infection occurs in one-third of all HIV-infected individuals. Liver disease has
      become more clinically significant among patients coinfected with HIV and HCV. Several
      studies have shown that coinfected individuals develop earlier and severe liver disease.
      Interferon with ribavirin has become the therapy of choice among people with non-genotype 1a.
      This is a pilot study to address the relationship of clinical response to combination therapy
      to the virologic and immunologic parameters. The study will also address the safety and
      efficacy of the peginterferon alfa-2b among HIV- infected individuals. The predictive ability
      of baseline HCV viral load, rate of decline of HCV viral load, HIV viral load and CD4 counts
      to the clinical response of chronic hepatitis to peginterferon and ribavirin will also be
      studied. Approximately sixty patients who are infected with both HIV and HCV and also have
      evidence of fibrosis will receive peginterferon alfa-2b and ribavirin for 48 weeks. In order
      to enroll sixty patients for this study, we will be screening a total of 180 patients. During
      the 72 weeks study these patients will be monitored for HCV viral load, and other HIV viral
      load and CD4 counts. Viral kinetics will also be monitored closely and the slope of second,
      slower phase decline of HCV viral load, which corresponds to the rate of infected cell death
      presumably may lead to sustained hepatitis C virologic response. The results of the study
      will enable us to better delineate the possible predictors of sustained response to
      peginterferon and ribavirin. The safety and tolerability of a combination therapy with
      peginterferon and ribavirin among HIV-infected individuals on antiretroviral therapy will
      further define the standard therapy of chronic hepatitis C in HIV-infected individuals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Viral Decline at Day 3 &amp; 28 With Predictors of Post Treatment Response</measure>
    <time_frame>Day 3 and Day 28</time_frame>
    <description>HCV viral kinetics were used to predict rates of sustained virology response (SVR) in HIV/HCV connected subjects.
Measure was determined by analyzing the population of participants with virologic decline of more than 1.0 log at day 3 combined with viral load of less than 5.0 log IU/ml at day 28 to predict sustained virology response</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly Injection of peginterferon alfa-2b and weight based ribavirin (1-1.2g/day) for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2b</intervention_name>
    <description>Weekly injections for 48 weeks of a dose of 1.5mcg/Kg per week subcutaneously</description>
    <arm_group_label>1</arm_group_label>
    <other_name>PegIntron</other_name>
    <other_name>PEG-Intron</other_name>
    <other_name>PegIntron Redipen</other_name>
    <other_name>Sylatron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Weight based Ribavirin dosing 1-1.2grams/day in divided (twice daily) doses for a total duration of 48 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ICN-1229</other_name>
    <other_name>Copegus</other_name>
    <other_name>Rebetol</other_name>
    <other_name>Ribasphere</other_name>
    <other_name>RBV</other_name>
    <other_name>RTCA</other_name>
    <other_name>Rebretron</other_name>
    <other_name>Ribav</other_name>
    <other_name>Ribavirine</other_name>
    <other_name>Tribavirin</other_name>
    <other_name>Vilona</other_name>
    <other_name>Viramid</other_name>
    <other_name>Virazid</other_name>
    <other_name>Virazole</other_name>
    <other_name>CAS Number: 36791-04-5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Age greater than or equal to 18 years.

        Documentation of HIV-1 infection by any licensed ELISA test and confirmed by a Western
        Blot.

        Documentation of Hepatitis C infection by demonstration of a positive test for hepatitis C
        antibody.

        HCV RNA level greater than 2000 IU/ml by bDNA.

        Infected with HCV genotype 1.

        Histopathologic features consistent with chronic hepatitis C on liver biopsy at the time of
        enrollment.

        Patients with CD4 greater than 300 cells/mm(3).

        Ability to sign informed consent and willingness to comply with the study requirements and
        clinic policies.

        Serum creatinine less than 1.5 mg/dL.

        Serum phosphorus greater than or equal to 2.2 mg/dL (normal range NIH 2.3-4.3 mg/dL).

        Neutrophil count greater than or equal to 1000 cells/mm(3).

        Platelets greater than or equal to 75,000/mm(3).

        Hemoglobin greater than or equal to 8.0 mg/dL.

        ALT less than 7 times the NIH upper limit of normal.

        Serum lipase less than 1.5 times the NIH upper limit of normal.

        Not pregnant or breast-feeding. Pregnancy test must be negative within two weeks prior to
        dosing with study medications.

        If capable of pregnancy: use of effective contraception during study: effective
        contraception methods include abstinence, surgical sterilization of either partner, barrier
        methods such as diaphragm, condom, cap or sponge, or use of hormonal contraception with an
        anti-HIV regimen that will not alter metabolism of hormonal contraception. This is advised
        on the basis of using ribavirin, which may have a potential teratogenic effect in pregnant
        women.

        Need to have a primary doctor outside OP8 who will be taking care of the patients for their
        HIV infection and liver disease.

        Willing to designate a person for durable power of attorney on the NIH form for medical
        research and medical care purposes at the NIH Clinical Center.

        Ability to learn how to safely inject medication subcutaneously.

        EXCLUSION CRITERIA:

        PT-INR (in the absence of anti-cardiolipin antibody) prolonged by greater than 2 seconds.

        Organ transplant recipient.

        Elevated alpha-fetoprotein level (greater than 100 ng/mL).

        Coexisting neoplastic disease requiring cytotoxic therapy.

        Child Pugh's class B.

        Severe cardiac or pulmonary decompensation.

        Severe liver decompensation or advanced cirrhosis patients.

        Severe psychiatric disorder that would interfere with the adherence to protocol
        requirements.

        Preexisting autoimmune disorders including inflammatory bowel diseases, psoriasis, and
        optic neuritis.

        Preexisting uncontrolled seizure disorder.

        Severe retinopathy.

        Hemoglobinopathy

        Direct bilirubin more than or equal to 2 times ULN.

        No patients using long term systemic corticosteroids, immunosuppressives, or cytotoxic
        agents within 60 days of enrollment into the trial.

        Chronic viral hepatitis of any other etiology other than hepatitis C.

        Active systemic infections other than hepatitis C and HIV.

        Liver disease caused by reasons other than hepatitis C like HBV, HDV, Wilson's
        hemochromatosis, autoimmune hepatitis (ANA greater than 160) except history of
        drug-associated hepatitis with discontinuation of the causative agent.

        Hepatic mass suggestive of hepatocellular carcinoma.

        Current alcohol or substance abuse that potentially could interfere with patient
        compliance.

        Significant heart failure.

        Evidence of esophageal varices.

        Any systemic illness that will make it unlikely that the subject will be able to return to
        NIH for the required study visits.

        Evidence of gastrointestinal malabsorption or chronic nausea or vomiting.

        Male partners of pregnant women.

        Currently taking didanosine (ddl or Videx-EC or Videx) as part of antiretroviral regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyam Kottilil, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rozenberg L, Haagmans BL, Neumann AU, Chen G, McLaughlin M, Levy-Drummer RS, Masur H, Dewar RL, Ferenci P, Silva M, Viola MS, Polis MA, Kottilil S. Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. AIDS. 2009 Nov 27;23(18):2439-50. doi: 10.1097/QAD.0b013e32832ff1c0.</citation>
    <PMID>19898214</PMID>
  </results_reference>
  <results_reference>
    <citation>Avidan NU, Goldstein D, Rozenberg L, McLaughlin M, Ferenci P, Masur H, Buti M, Fauci AS, Polis MA, Kottilil S. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts. J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):452-8. doi: 10.1097/QAI.0b013e3181be7249.</citation>
    <PMID>19797971</PMID>
  </results_reference>
  <results_reference>
    <citation>Allison RD, Katsounas A, Koziol DE, Kleiner DE, Alter HJ, Lempicki RA, Wood B, Yang J, Fullmer B, Cortez KJ, Polis MA, Kottilil S. Association of interleukin-15-induced peripheral immune activation with hepatic stellate cell activation in persons coinfected with hepatitis C virus and HIV. J Infect Dis. 2009 Aug 15;200(4):619-23. doi: 10.1086/600107.</citation>
    <PMID>19594300</PMID>
  </results_reference>
  <results_reference>
    <citation>Nussenblatt V, McLaughlin M, Rehm CA, Lempicki RA, Brann T, Yang J, Proschan M, Highbarger HC, Dewar RL, Imamichi T, Koratich C, Neumann AU, Masur H, Polis MA, Kottilil S. Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients. AIDS Res Hum Retroviruses. 2007 Nov;23(11):1354-9. doi: 10.1089/aid.2007.0091.</citation>
    <PMID>18184077</PMID>
  </results_reference>
  <results_reference>
    <citation>Neumann A, Polis M, Rozenberg L, Jackson J, Reitano K, McLaughlin M, Koratich C, Dewar R, Masur H, Haagmans B, Kottilil S. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. AIDS. 2007 Sep 12;21(14):1855-65.</citation>
    <PMID>17721093</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu L, Kottilil S, Lempicki R, Yang J, McLaughlin M, Hu Z, Koratich C, Reitano KN, Rehm CA, Masur H, Wood B, Kleiner DE, Polis MA. Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR). AIDS Res Hum Retroviruses. 2006 Nov;22(11):1091-8.</citation>
    <PMID>17147494</PMID>
  </results_reference>
  <results_reference>
    <citation>Pau AK, McLaughlin MM, Hu Z, Agyemang AF, Polis MA, Kottilil S. Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin. AIDS Patient Care STDS. 2006 Sep;20(9):612-9.</citation>
    <PMID>16987047</PMID>
  </results_reference>
  <results_reference>
    <citation>Farel C, Suzman DL, McLaughlin M, Campbell C, Koratich C, Masur H, Metcalf JA, Robinson MR, Polis MA, Kottilil S. Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin. AIDS. 2004 Sep 3;18(13):1805-9.</citation>
    <PMID>15316341</PMID>
  </results_reference>
  <results_reference>
    <citation>Lempicki RA, Polis MA, Yang J, McLaughlin M, Koratich C, Huang DW, Fullmer B, Wu L, Rehm CA, Masur H, Lane HC, Sherman KE, Fauci AS, Kottilil S. Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis. 2006 Apr 15;193(8):1172-7. Epub 2006 Mar 13.</citation>
    <PMID>16544259</PMID>
  </results_reference>
  <results_reference>
    <citation>Sidique N, Kohli A, Shivakumar B, Migueles S, Subramanian GM, Naggie S, Polis MA, Masur H, Kottilil S. HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients. J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):e38-40. doi: 10.1097/QAI.0b013e31822d463f.</citation>
    <PMID>21921725</PMID>
  </results_reference>
  <results_reference>
    <citation>Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, Clark PJ, Patel K, Muir AJ, McHutchison JG, Schlaak JF, Trippler M, Shivakumar B, Masur H, Polis MA, Kottilil S. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology. 2012 Aug;56(2):444-54. doi: 10.1002/hep.25647. Epub 2012 Jul 2.</citation>
    <PMID>22331604</PMID>
  </results_reference>
  <results_reference>
    <citation>Osinusi A, Naggie S, Poonia S, Trippler M, Hu Z, Funk E, Schlaak J, Fishbein D, Masur H, Polis M, Kottilil S. ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. J Med Virol. 2012 Jul;84(7):1106-14. doi: 10.1002/jmv.23302.</citation>
    <PMID>22585729</PMID>
  </results_reference>
  <results_reference>
    <citation>Burbelo PD, Kovacs JA, Ching KH, Issa AT, Iadarola MJ, Murphy AA, Schlaak JF, Masur H, Polis MA, Kottilil S. Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patients. J Infect Dis. 2010 Sep 15;202(6):894-8. doi: 10.1086/655780.</citation>
    <PMID>20684729</PMID>
  </results_reference>
  <results_reference>
    <citation>Chary A, Winters MA, Kottilil S, Murphy AA, Polis MA, Holodniy M. Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients. J Infect Dis. 2010 Sep 15;202(6):889-93. doi: 10.1086/655784.</citation>
    <PMID>20677940</PMID>
  </results_reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2001</study_first_submitted>
  <study_first_submitted_qc>June 27, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2001</study_first_posted>
  <results_first_submitted>January 18, 2013</results_first_submitted>
  <results_first_submitted_qc>September 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 1, 2014</results_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Shyamasundaran Kottilil, M.D.</investigator_full_name>
    <investigator_title>Staff Clinician</investigator_title>
  </responsible_party>
  <keyword>Liver Disease</keyword>
  <keyword>Virologic Response</keyword>
  <keyword>Immune Mechanisms</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Eradication</keyword>
  <keyword>HIV</keyword>
  <keyword>Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were all recruited from other NIAID HIV clinical trials and from the nearby Maryland, Virginia and the District of Columbia HIV clinics</recruitment_details>
      <pre_assignment_details>Open label study. The participants were only excluded if they did not meet eligibility criteria, such as pregnancy, availability to make frequent clinic visits and able to meet laboratory safety criteria as described in the clinical protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Peginterferon Alfa-2b, Ribavirin</title>
          <description>Weekly Injection (Peginterferon alfa-2b)
Peginterferon Alfa-2b : Weekly injections for 48 weeks of a dose of 1.5mcg/Kg per week subcutaneously
Oral Pills (Ribavirin)
Ribavirin : Weight based Ribavirin dosing 1-1.2grams/day in divided (twice daily) doses for a total duration of 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peg-interefron Alfa 2b, Ribavirin</title>
          <description>Weekly Injection
Peginterferon alpha-2b : Weekly injections for 48 weeks of a dose of 1.5mcg/Kg per week subcutaneously
Oral Pills
Ribavirin : Weight based Ribavirin dosing 1-1.2grams/day in divided (twice daily) doses for a total duration of 48 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Viral Decline at Day 3 &amp; 28 With Predictors of Post Treatment Response</title>
        <description>HCV viral kinetics were used to predict rates of sustained virology response (SVR) in HIV/HCV connected subjects.
Measure was determined by analyzing the population of participants with virologic decline of more than 1.0 log at day 3 combined with viral load of less than 5.0 log IU/ml at day 28 to predict sustained virology response</description>
        <time_frame>Day 3 and Day 28</time_frame>
        <population>Participants with Virologic decline at both Day 3 and absolute HCV VL at Week 28 were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon Alfa-2b, Ribavirin</title>
            <description>Weekly Injection (Peginterferon alfa-2b)
Peginterferon Alfa-2b : Weekly injections for 48 weeks of a dose of 1.5mcg/Kg per week subcutaneously
Oral Pills (Ribavirin)
Ribavirin : Weight based Ribavirin dosing 1-1.2grams/day in divided (twice daily) doses for a total duration of 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Viral Decline at Day 3 &amp; 28 With Predictors of Post Treatment Response</title>
          <description>HCV viral kinetics were used to predict rates of sustained virology response (SVR) in HIV/HCV connected subjects.
Measure was determined by analyzing the population of participants with virologic decline of more than 1.0 log at day 3 combined with viral load of less than 5.0 log IU/ml at day 28 to predict sustained virology response</description>
          <population>Participants with Virologic decline at both Day 3 and absolute HCV VL at Week 28 were analyzed</population>
          <units>participants with post treatment svr</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Peg-interefron Alfa 2b, Ribavirin</title>
          <description>Weekly Injection
Peginterferon alpha-2b : Weekly injections for 48 weeks of a dose of 1.5mcg/Kg per week subcutaneously
Oral Pills
Ribavirin : Weight based Ribavirin dosing 1-1.2grams/day in divided (twice daily) doses for a total duration of 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Changes</sub_title>
                <description>Transient or mild discomfort; no limitation in activity; no medical intervention/therapy required.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carcinoma</sub_title>
                <description>Mild to moderate limitation in activity; some assistance may be needed; no or minimal medical intervention required.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Unusual affect or behavior</sub_title>
                <description>Marked limitation in activity; some assistance usually required; medical intervention/therapy required.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Hemoglobin decreased</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Neutrophil count decreased</description>
                <counts group_id="E1" events="43" subjects_affected="15" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Shyam Kottilil</name_or_title>
      <organization>NIAID/NIH</organization>
      <phone>301-435-036</phone>
      <email>skottilil@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

